DNX Corp. has raised $12.1 million in second-round venturefinancing, exceeding its original goal by $4 million, thecompany said on Friday.

Existing DNX investors participating in this round wereBiotechnology Investments Ltd., Domain Associates, DSVPartners, Fidelity Capital, Greylock, Ohio University Fund Inc.,S.R. One and Venrock.

New investors were Advent International Corp., BayviewInvestors Ltd., Copley Venture Partners, Hancock VenturePartners, Alan Patricof Associates and TVM Techno VentureManagement.

Including this round, DNX has raised $19.3 million since 1988.

The funds will be used to support DNX's three core programs:development of transgenic swine that produce humanhemoglobin as a red blood cell substitute; development oftransgenic animal models for drug safety and efficacy testing;and development of transgenic swine as universal tissue andorgan donors.

In June, the Princeton, N.J., company said it had developedthree transgenic pigs that produce human hemoglobin. Othercompanies hoping to tap the $8 billion to $10 billion worldmarket for blood substitutes include Somatogen Inc., BiopureCorp., Enzon Inc. and Biosource Genetics Corp.

(c) 1997 American Health Consultants. All rights reserved.